<DOC>
	<DOCNO>NCT03104699</DOCNO>
	<brief_summary>This Phase 1 , open-label , 3 + 3 dose-escalation trial subject metastatic locally advanced solid tumor , consecutive Phase 2 expansion evaluate efficacy subject recurrent , unresectable , metastatic ( advanced ) cervical cancer progress platinum doublet .</brief_summary>
	<brief_title>Phase 1 / 2 Study AGEN2034 Advanced Tumors Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Safety Cohort ( Dose Escalation ) 1 . Signed write informed consent . 2 . Age ≥18 year . 3 . Histologically cytologically proven metastatic locally advanced solid tumor standard therapy exist standard therapy fail . Availability tumor archival material fresh biopsy optional subject dose escalation . 4 . ECOG performance status 0 1 trial entry estimate life expectancy ≥3 month . 5 . Evidence objective disease . A measurable lesion necessary . 6 . Adequate hematological function define white blood cell ( WBC ) count ≥3 × 10^9/L ; absolute neutrophil count ( ANC ) ≥1.5 × 10^9/L ; lymphocyte count ≥0.5 × 10^9/L ; platelet count ≥100 × 10^9/L ; hemoglobin ≥9 g/dL ( may transfuse ) . 7 . Adequate hepatic function , define total bilirubin ≤1.5 × upper limit normal ( ULN ) ; AST ≤2.5 × ULN ; ALT ≤2.5 × ULN . For subject document metastatic disease liver , AST ALT : ≤5 × ULN . 8 . Adequate renal function , define estimate creatinine clearance &gt; 50 mL/min accord CockcroftGault formula measure 24hour creatinine clearance ( local institutional standard method ) . 9 . Effective contraception male female subject risk conception exists . Efficacy Expansion Cohort ( SecondLine Cervical Cancer ) 1 . Signed write informed consent . 2 . Age ≥18 year . 3 . Subjects must recurrent , unresectable , metastatic cervical cancer relapse platinumcontaining doublet administer treatment advanced ( recurrent , unresectable , metastatic ) disease . Subjects must persistent , recurrent , metastatic squamous cell carcinoma , adenosquamous carcinoma adenocarcinoma cervix , document disease progression ( disease amenable curative therapy ) . Note : The following cervical tumor eligible : minimal deviation/adenoma malignum , gastric type adenocarcinoma , clear cell carcinoma mesonephric carcinoma . Histologic confirmation original primary tumor require via pathology report . Subjects must one prior systemic chemotherapeutic regimen management persistent , recurrent , metastatic carcinoma cervix ( e.g. , paclitaxel/cisplatin , paclitaxel/cisplatin/bevacizumab ) . Chemotherapy administer concurrently primary radiation ( e.g. , weekly cisplatin ) count systemic chemotherapy regimen . Adjuvant chemotherapy give follow completion radiation therapy ( concurrent chemotherapy radiation therapy ) count systemic chemotherapy regimen ( e.g. , paclitaxel carboplatin ≤4 cycle ) . Note : Subjects receive &gt; 1 prior regimen eligible . 4 . ECOG performance status 0 1 trial entry estimate life expectancy ≥3 month . 5 . Availability formalinfixed paraffinembedded block contain tumor tissue 7 unstained tumor slide suitable PDL1 expression assessment . 6 . Availability tissue HPV testing ( paraffin block one 7µm section slide ) . 7 . Disease must measurable , ≥1 unidimensional measurable lesion per RECIST 1.1 . 8 . Adequate hematological function , define WBC ≥3 × 10^9/L ; ANC ≥1.5 × 10^9/L ; lymphocyte count ≥0.5 × 10^9/L ; platelet count ≥100 × 10^9/L ; hemoglobin ≥9 g/dL ( may transfuse ) . 9 . Adequate hepatic function , define total bilirubin ≤1.5 × ULN ; AST ≤2.5 × ULN ; ALT ≤2.5 × ULN . 10 . Adequate renal function , define estimate creatinine clearance &gt; 30 mL/min accord CockcroftGault formula measure 24hour creatinine clearance ( local institutional standard method ) . 11 . Effective contraception male female subject risk conception exists . Note : Effects study drug develop human fetus unknown . Thus , woman childbearing potential men must agree use effective contraception , define 2 barrier method , 1 barrier method spermicide , intrauterine device use oral female contraceptive . Effective contraception must use 30 day first study drug administration , duration trial participation , ≥60 day stop trial participation . Should woman become pregnant suspect pregnant partner participate trial , treat physician inform immediately . Safety Expansion Cohorts 1 . Concurrent treatment nonpermitted drug . 2 . Prior therapy antibody/drug target Tcell coregulatory protein ( immune checkpoint ) antiPD1 , antiPDL1 , anticytotoxic Tlymphocyte antigen 4 ( CTLA4 ) antibody . For subject metastatic melanoma , prior treatment CTLA4blocking antibody permissible . 3 . Concurrent anticancer treatment ( e.g. , cytoreductive therapy , radiotherapy except palliative bonedirected radiotherapy , immune therapy , cytokine therapy except erythropoietin ) within 28 day start trial treatment ; major surgery within 28 day start trial treatment ( exclude prior diagnostic biopsy ) ; use hormonal agent within 7 day start trial treatment , except subject castrationresistant prostate cancer ( CRPC ) , may remain treatment luteinizing hormonereleasing hormone agonist antagonist ; use investigational drug within 28 day start trial treatment . Note : Small molecule antibody target therapy permissible &lt; 14 day start trial treatment . 4 . Subjects receive immunosuppressive agent ( steroid ) reason taper drug 14 day initiation study treatment . Steroids minimal systemic effect ( topical , inhalation ) allow . Note : Subjects receive bisphosphonate denosumab eligible provide treatment initiated ≥14 day first dose AGEN2034 . Note : Use inhale topical corticosteroid permit . Note : Steroid premedication radiographic image dye allergy permit . 5 . Previous malignant disease ( target malignancy investigated trial ) within last 5 year , exception basal squamous cell carcinoma skin . 6 . Rapidly progressive disease . 7 . Active history central nervous system metastasis . 8 . Receipt organ transplantation , include allogeneic stemcell transplantation . 9 . Significant acute chronic infection , include : Known history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) . Positive test hepatitis B virus ( HBV ) surface antigen and/or confirmatory hepatitis C virus ( HCV ) RNA ( antiHCV antibody test positive ) . 10 . Active history autoimmune disease ( subject diabetes type 1 , vitiligo , psoriasis , hypo , hyperthyroid disease require immunosuppressive treatment eligible ) immunodeficiency . 11 . Known severe hypersensitivity reaction monoclonal antibody ( NCI CTCAE grade ≥3 ) , history anaphylaxis , uncontrolled asthma ( i.e. , ≥3 feature partly control asthma ) . 12 . Persisting toxicity relate prior therapy NCI CTCAE grade &gt; 1 severity . Sensory neuropathy grade ≤2 acceptable . 13 . Pregnancy breast feed . 14 . Known alcohol drug abuse . 15 . Clinically significant ( i.e. , active ) cardiovascular disease : cerebral vascular accident/stroke ( &lt; 6 month enrollment ) , myocardial infarction ( &lt; 6 month enrollment ) , unstable angina , congestive heart failure ( New York Heart Association class ≥II ) , serious uncontrolled cardiac arrhythmia require medication . 16 . All significant disease ( e.g. , inflammatory bowel disease ) , opinion investigator , might impair subject 's tolerance trial treatment . 17 . Any psychiatric condition would prohibit understanding rendering informed consent . 18 . Legal incapacity limit legal capacity . 19 . Vaccination within 4 week first dose AGEN2034 study except administration inactivate vaccine ( e.g. , inactivate influenza vaccine ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Antibodies</keyword>
	<keyword>Immunologic effect</keyword>
	<keyword>Physiological Effects Drugs</keyword>
</DOC>